CG Oncology: Late-stage study paves the way for early bladder cancer therapy - With a 30% stock increase to a new all-time high!
Reading Time: 3 minutes
Novel therapy using special viruses to combat cancer cells offers urgently needed treatment options for the growing number of bladder cancer patients. Phase 3 study PIVOT-006 demonstrates prolonged disease-free survival. Stock jumps over 30% to an all-time high! Focus on oncolytic viruses in the urology market The company CG Oncology (CGON) specializes in combating cancer in the urological field using a unique approach: they utilize special viruses that specifically target cancer cells. Their main drug, Cretostimogene, is intended for...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.

